Details for New Drug Application (NDA): 209941
✉ Email this page to a colleague
NDA 209941 describes SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, which is a drug marketed by Alkem Labs Ltd, Bionpharma, Novel Labs Inc, Pai Holdings, Strides Pharma, and Taro, and is included in six NDAs. It is available from five suppliers. Additional details are available on the SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE profile page.
The generic ingredient in SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE is magnesium sulfate; potassium sulfate; sodium sulfate. There are one hundred and forty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the magnesium sulfate; potassium sulfate; sodium sulfate profile page.
The generic ingredient in SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE is magnesium sulfate; potassium sulfate; sodium sulfate. There are one hundred and forty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the magnesium sulfate; potassium sulfate; sodium sulfate profile page.
Summary for 209941
| Tradename: | SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE |
| Applicant: | Pai Holdings |
| Ingredient: | magnesium sulfate; potassium sulfate; sodium sulfate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT | ||||
| Approval Date: | Jul 15, 2024 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
